Social phobia: Issues in assessment and management

Epilepsia

Volumn 40, Issue SUPPL. 6, 1999, Pages s60-s65

  Connor, Kathryn M ^a   Davidson, Jonathan R T ^a   Sutherland, Suzanne ^a   Weisler, Richard ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Anxiety; Pharmacotherapy; Social phobia

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROFAROMINE; BUSPIRONE; GABAPENTIN; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE INHIBITOR;

ANXIETY; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG INDICATION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SOCIAL EVOLUTION; SOCIAL PHOBIA;

EID: 0032840683     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb00935.x     Document Type: Conference Paper

References (51)

1. Magee WJ, Eaton WW, Wittchen HU, McGonagle KA, Kessler RC. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry 1996;53:159-68.
2. Schneier M, Johnson J, Hornig CD, Liebowitz MR, Weissman MM. Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry 1992;49:282-8.
3. Fyer AJ. Heritability of social anxiety: a brief review. J Clin Psychiatry 1993;54(suppl):10-2.
4. Skre I, Onstad S, Torgersen S, Lygren S, Kringlen E. A twin study of DSM-III-R anxiety disorders. Ada Psychiatr Scand 1993;88: 85-92.
5. Marks IM. The classification of phobic disorders. Br J Psychiatry 1970;116:377-86.
6. Davidson JR, Hughes DC, George LK, Blazer DG. The boundary of social phobia. Exploring the threshold. Arch Gen Psychiatry 1994;51:975-83.
7. Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993;13: 423-8.
8. Tiihonen J, Kuikka J, Bergstrom K, Lepola U, Koponen H, Leinonen E. Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry 1997;154:239-42.
9. Wilhelm S, Otto MW, Zucker BG, Pollack MH. Prevalence of body dysmorphic disorder in patients with anxiety disorders. J Anxiety Disord 1997;11:499-502.
10. Oberlander EL, Schneier FR, Liebowitz MR. Physical disability and social phobia. J Clin Psychopharmacol 1994;14:139-43.
11. Davidson JR, Hughes DL, George LK, Blazer DG. The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study. Psychol Med 1993;23:709-18.
12. Weiller E, Bisserbe JC, Boyer P, Lepine JP, Lecrubier Y. Social phobia in general health care: an unrecognized undertreated disabling disorder. Br J Psychiatry 1996;168:169-74.
13. Turner SM, Beidel DC, Jacob RG. Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol 1994;67: 350-8.
14. Heimberg RG, Juster HR. Treatment of social phobia in cognitive-behavioral groups. J din Psychiatry 1994;55(suppl):38-46.
15. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry 1992;49:290-300.
16. Gelernter CS, Uhde TW, Cimbolk P, et al. Cognitive-behavioral and pharmacological treatments of social phobia: a controlled study. Arch Gen Psychiatry 1991;48:938-45.
17. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R. Pharmacotherapy of social phobia: a controlled study of moclobemide and phenelzine. Br J Psychiatry 1992;161:353-60.
18. Fahlen T, Humble M, Koczkas C, Nillso HL. Social phobia and its treatment with brofaromine: efficacy regarding social phobia symptoms and personality traits [Abstract]. Clin Neuropharmacol 1992;15(suppl 1):64B.
19. Bisserbe JC, Lepine JP, and the GRP Group. Moclobemide in social phobia: a pilot open study. Clin Neuropharmacol 1994;17 (suppl 1):S88-94.
20. International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia: a double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci 1997;247:71-80.
21. Versiani M, Nardi AE, Mundim FD, Pinto S, Saboya E, Kovacs R. The long-term treatment of social phobia with moclobemide. Int J Clin Psychopharmacol 1996:11(suppl 3):83-8.
22. Noyes R, Moroz G, Davidson JRT, et al. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol 1997;17:247-54.
23. Schneier FR, Goetz D, Campeas R, Fallon B, Marshall R, Liebowitz MR. Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 1998;172:70-7.
24. Fahlen T, Nillson HL, Borg K, Humble M, Pauli U. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin reuptake inhibitor brofaromine: a double-blind, placebo-controlled study. Acta Psychiatry Scand 1995;92:351-8.
25. van Vliet IM, den Boer JA, Westenberg HGM. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacol 1992;2:21-9.
26. Lott M, Greist JH, Jefferson JW, et al. Brofaromine for social phobia, a multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol 1997;17:255-60.
27. Connor KM, Davidson JR, Potts NL, et al. Discontinuation of clonazepam in the treatment of social phobia. J Clin Psychopharmacol 1998;18:373-8.
28. Van Ameringen M, Mancini C, Streiner DL. Fluoxetine efficacy in social phobia. J Clin Psychiatry 1993;54:27-32.
29. Black B, Uhde TW, Tancer ME. Fluoxetine for the treatment of social phobia [Letter]. J Clin Psychopharmacol 1992;12:293-5.
30. Czepowicz VD, Johnson MR, Lydiard RB, et al. Sertraline in social phobia [Letter]. J Clin Psychopharmacol 1995;15:372-3.
31. Martins EA, Pigott TA, Bernstein SE, et al. Sertraline in the treatment of patients with social phobia. Anxiety 1994/1995;1:291-7.
32. Munjack DJ, Flowers C, Eagan TV. Sertraline in social phobia. Anxiety 1994/1995;1:196-8.
33. Van Ameringen M, Mancini C, Streiner D. Sertaline in social phobia. J Affect Disord 1994;31:141-5.
34. Mancini C, Van Ameringen M, Paroxetine in social phobia. J Clin Psychiatry 1996;57:519-22.
35. van Vliet IM, den Boer JA, Westenberg HGM. Psychopharmacological treatment of social phobia: a double-blind placebo-controlled study with fluvoxamine. Psychopharmacology 1994; 115:128-31.
36. Stein MB, Fyer AJ, Davidson JR, et al. Fluvoxamine treatment of Social Phobia (social anxiety disorder): a double-blind placebo-controlled study. Am J Psych 1999;156:756-60.
37. Katzelnick DL, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995;152:1368-71.
38. Stein MB, Chartier MJ, Hazen AL, et al. Paroxetine in the treatment of generalized social phobia: open-level treatment and double-blind placebo-controlled discontinuation. J Clin Psychopharmacol 1996;16:218-22.
39. Miner CM, Davidson JR, Potts NL, Tupler LA, Charles HC, Krishman KR. Brain fluoxetine measurements using fluorine magnetic resonance spectroscopy in patients with social phobia. Biol Psychiatry 1995;38:696-8.
40. Simpson HB, Schneier FR, Campeas RB, et al. Imipramine in the treatment of social phobia. J Clin Psychopharmacol 1998;18: 132-5.
41. Kelsey JE. Venlafaxine in social phobia. Psychopharmacol Bull 1995;31:767-71.
42. Lepola U, Koponen H, Lienonen E. Citalopram in the treatment of social phobia: a report of three cases. Pharmacopsychiatry 1994; 27:186-8.
43. Clark DB, Agras WS. The assessment and treatment of performance anxiety in musicians. Am J Psychiatry 1991;148:598-605.
44. van Vliet IM, den Boer JA, Westenberg HGM, Ho Pian KL. Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry 1997;58:164-8.
45. Schneier FR, Saoud JB, Campeas R, et al. Buspirone in social phobia. J Clin Psychopharmacol 1993;13:251-6.
46. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol [in press].
47. Liebowitz MR. Pharmacotherapy of social phobia. J Clin Psychiatry 1994;54(suppl):31-5.
48. Davidson JR, Miner CM, De Veaugh-Geiss J, Tupler LA, Colket JT, Potts NL. The Brief Social Phobia Scale: a psychometric evaluation. Psychol Med 1997;27:161-6.
49. Schlicker E, Reimann W, Gothert M. Gabapentin decreases monoamine release without affecting acetylcholine release in the brain. Arzneimittelforschung 1985;35:1347-9.
50. Connor KM, Davidson JRT, Churchill LE, et al. Psychometric properties of the Social Phobia Inventory (SPIN): a new self-rating scale. Presented at the National Institute of Mental Health's New Clinical Drug Evaluation Unit Meeting. June 1-4, 1999. Boca Raton, Florida.
51. Kobak KA, Taylor LH, Dotti SL, et al. Computerized screening for psychiatric disorders in an outpatient community mental health clinic. Psychiatr Serv 1997;48:1048-57.